ZLDPY catalysts
Catalysts and events linked to ZLDPY, newest first.
ZLDPY stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Survodutide Phase III Trial Achieves 13.1% Weight Loss in T2D Obesity 2026-10-01 · Up | milestone and future royalty cash flow accretion on regulatory filing progress | Source explicitly names Phase III trial success for Zealand Pharma's licensed asset survodutide. | Not recorded |
| Survodutide Delivers Up to 13.1% Weight Loss in Phase III Trial 2026-10-01 · Up | royalty and milestone revenue from Phase III clinical success | Zealand Pharma co-develops survodutide with Boehringer Ingelheim. | Not recorded |
| Survodutide achieves 13.1% weight loss in Phase III trial for obesity and diabetes 2026-10-01 · Up | commercialization royalty stream valuation and milestone payments on Phase III clinical success | Zealand Pharma co-developed survodutide with Boehringer Ingelheim. | Not recorded |
| Survodutide Achieves 13.1% Weight Loss in Phase III Diabetes and Obesity Trial 2026-10-01 · Up | milestone and future commercial royalty repricing on Phase III success | Zealand Pharma co-developed and licenses survodutide to Boehringer Ingelheim. | Not recorded |
| Survodutide Phase III Trial Achieves Up to 13.1% Weight Loss in Diabetes Cohort 2026-10-01 · Up | milestone and future royalty cash flow accretion from Phase III validation | Zealand Pharma co-developed survodutide alongside Boehringer Ingelheim. | Not recorded |
| Boehringer and Zealand Report 13.1% Weight Loss in Survodutide Phase III Trial 2026-10-01 · Up | royalty revenue and milestone payment repricing upon Phase III clinical success | Zealand Pharma co-invented survodutide and is entitled to milestones and tiered royalties. | Not recorded |
| Survodutide Delivers 13.1% Weight Loss in Phase III Diabetes and Obesity Trial 2026-10-01 · Up | biotech pipeline derisking and future commercial royalty streams on survodutide | Zealand Pharma announced positive Phase III SYNCHRONIZE-2 trial results. | Not recorded |
| Survodutide Achieves 13.1% Weight Loss in Phase III Obesity/T2D Trial 2026-10-01 · Up | royalty stream and milestone revenue expansion from Phase III clinical success | Zealand Pharma partner Boehringer Ingelheim announced positive SYNCHRONIZE-2 13.1% weight loss results. | Not recorded |
Do these developments change your position?
Review ZLDPY alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-10-01Survodutide Achieves 13.1% Weight Loss in Phase III Diabetes and Obesity TrialZLDPY
- 2026-10-01Survodutide Phase III Trial Meets Endpoints with Up to 13.1% Weight Loss in T2D ObesityZLDPY
- 2026-10-01Boehringer and Zealand Report 13.1% Weight Loss in Phase III TrialZLDPY
- 2026-10-01Survodutide achieves 13.1% weight loss in Phase III trial for obesity and diabetesZLDPY
- 2026-10-01Boehringer and Zealand Report 13.1% Weight Loss in Survodutide Phase III TrialZLDPY
- 2026-10-01Survodutide Phase III Trial Achieves 13.1% Weight Loss in T2D ObesityZLDPY
- 2026-10-01Survodutide Phase III Trial Meets Endpoints with Up to 13.1% Weight Loss in T2D ObesityZLDPY
- 2026-10-01Survodutide Delivers 13.1% Weight Loss in Phase III Obesity/T2D TrialZLDPY
- 2026-10-01Boehringer and Zealand Report 13.1% Weight Loss in Phase III TrialZLDPY
- 2026-10-01Survodutide Hits 13.1% Weight Loss in Phase III Obesity/Type 2 Diabetes TrialZLDPY
- 2026-10-01Survodutide Achieves 13.1% Weight Loss in Phase III Obesity/T2D TrialZLDPY
- 2026-10-01Survodutide Delivers Up to 13.1% Weight Loss in Phase III TrialZLDPY
- 2026-10-01Survodutide achieves 13.1% weight loss in Phase III trial for obesity and diabetesZLDPY
- 2026-10-01Survodutide Achieves 13.1% Weight Loss in Phase III Diabetes and Obesity TrialZLDPY
- 2026-10-01Survodutide Phase III Trial Achieves Up to 13.1% Weight Loss in Diabetes CohortZLDPY
- 2026-10-01Survodutide Delivers 13.1% Weight Loss in Phase III Diabetes and Obesity TrialZLDPY
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.